Document
type: Class

Continuant
type: Class

Entity
type: Class

Review
type: Class

Generically Dependent Continuant
type: Class

CB-256063
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: Current advances in the algae-made biopharmaceuticals field

RDF description of Current advances in the algae-made biopharmaceuticals field - http://orbis.uaslp.mx/vivo/individual/scopus7171
rights: termsOfUse
date: 2026-08-24T21:50:54
publisher: vivo
type: Document

Article
type: Class

Information Content Entity
type: Class

Expert Opinion on Biological Therapy
type: Thing
publication venue for: Current advances in the algae-made biopharmaceuticals field
type: Generically Dependent Continuant
type: Journal
type: Information Content Entity
type: Periodical
type: Entity
type: Document
type: Collection
type: Continuant

Current advances in the algae-made biopharmaceuticals field
doi: 10.1080/14712598.2020.1739643
freetext keyword: Antibodies; Chlamydomonas reinhardtii; chloroplast transformation; genetic engineering; oral delivery; Schizochytrium sp.; viral vector disulfide bond; downstream processing; drug industry; large scale production; microalga; nonhuman; product development; protein expression; Review; scale up; drug industry; genetics; growth, development and aging; human; metabolism; microalga; antibody; biological product; growth hormone; peptide; vaccine; Antibodies; Biological Products; Drug Industry; Growth Hormone; Humans; Microalgae; Peptides; Vaccines
type: Document
related by: authorship_46274
related by: authorship_46273
abstract: Introduction: The biopharmaceuticals industry demands new production platforms to address several challenges; such as cost reduction to make biologics accessible in low-income countries, safety enhancement of the product, development of products administered by noninvasive routes, and expansion of potential biosimilars and biobetters. Microalgae are emerging hosts for biopharmaceuticals production with the potential to meet such requirements. Areas covered: Nowadays successful cases on the production of vaccines, antibodies, antimicrobial peptides, growth factors/cytokines, and hormones in algae have been reported. This review comprises an updated outlook covering protein expression strategies, a compilation of functional biopharmaceuticals produced in algae, and companies investing in this technology. Expert opinion: Key perspectives for the field include optimizing yields, scaling up production and completing preclinical trials. The experience from the field of plant-made biopharmaceuticals is commented as a key reference that will aid in the development of the algae-made biopharmaceuticals field. © 2020, © 2020 Informa UK Limited, trading as Taylor %26 Francis Group.
chemicalscas: growth hormone, 36992-73-1, 37267-05-3, 66419-50-9, 9002-72-6; Antibodies; Biological Products; Growth Hormone; Peptides; Vaccines
type: Thing
origen: scopus
date time value: review date 7172
most specific type: Review
crisid: 7172
issue: 7
page start: 751
most specific type: Document
page end: 766
related by: authorship_46270
type: Information Content Entity
e iscopus: 2-s2.0-85082338364
has publication venue: Expert Opinion on Biological Therapy
type: Entity
related by: authorship_46272
type: Article
type: Generically Dependent Continuant
related by: authorship_46271
volume: 20
pmid: 32142617
has funding vehicle: CB-256063
estado: published
type: Continuant
type: Review